NovImmune receives CHF 62.5m

BZ Bank has led a CHF 63m investment round in Geneva-based biotechnology company NovImmune SA, alongside new and existing investors including Novartis Venture Fund, Aravis Venture and Lombard Odier Darier Hentsch, among others.

NovImmune SA is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. Two compounds are in clinical development, with the most advanced in clinical phase II. The lead product, NI-0401/anti-CD3, is currently being tested on Crohn's disease, type 1 diabetes and transplantation. BZ Bank led the EUR37m series-B financing in the company in late 2006. The company was founded in 1998.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Industry
• France